HomeCompareTHRX vs PM

THRX vs PM: Dividend Comparison 2026

THRX yields 49.20% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THRX wins by $328.5K in total portfolio value
10 years
THRX
THRX
● Live price
49.20%
Share price
$4.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$378.0K
Annual income
$75,635.59
Full THRX calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — THRX vs PM

📍 THRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHRXPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THRX + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THRX pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THRX
Annual income on $10K today (after 15% tax)
$4,182.04/yr
After 10yr DRIP, annual income (after tax)
$64,290.25/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, THRX beats the other by $62,172.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THRX + PM for your $10,000?

THRX: 50%PM: 50%
100% PM50/50100% THRX
Portfolio after 10yr
$213.8K
Annual income
$39,063.81/yr
Blended yield
18.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

THRX
Analyst Ratings
8
Buy
4
Hold
Consensus: Buy
Altman Z
10.0
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THRX buys
0
PM buys
0
No recent congressional trades found for THRX or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHRXPM
Forward yield49.20%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$378.0K$49.6K
Annual income after 10y$75,635.59$2,492.02
Total dividends collected$300.5K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: THRX vs PM ($10,000, DRIP)

YearTHRX PortfolioTHRX Income/yrPM PortfolioPM Income/yrGap
1← crossover$15,620$4,920.05$11,648$408.29+$4.0KTHRX
2$23,896$7,182.37$13,589$495.90+$10.3KTHRX
3$35,837$10,268.90$15,877$603.21+$20.0KTHRX
4$52,739$14,393.12$18,580$734.88+$34.2KTHRX
5$76,226$19,795.56$21,781$896.75+$54.4KTHRX
6$108,302$26,739.69$25,578$1,096.12+$82.7KTHRX
7$151,389$35,506.13$30,092$1,342.17+$121.3KTHRX
8$208,372$46,385.07$35,470$1,646.46+$172.9KTHRX
9$282,625$59,667.49$41,892$2,023.58+$240.7KTHRX
10$378,044$75,635.59$49,578$2,492.02+$328.5KTHRX

THRX vs PM: Complete Analysis 2026

THRXStock

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Full THRX Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this THRX vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THRX vs SCHDTHRX vs JEPITHRX vs OTHRX vs KOTHRX vs MAINTHRX vs MOTHRX vs BTITHRX vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.